Abstract
Objective To compare the NHS Health Check Programme with the Polypill Prevention Programme in the primary prevention of heart attacks and strokes.
Design Use of published data and methodology to produce flow charts of the two programmes to determine screening performance and heart attacks and strokes prevented.
Setting The UK population.
Intervention The NHS Health Check Programme using a QRisk score on people aged 40-74 to select those eligible for a statin is compared with the Polypill Prevention programme in people aged 50 or more to select people for a combination of a statin and 3 low dose blood pressure lowering agents. In both programmes people had no history of heart attack or stroke.
Main outcome measures In 1000 people the number of heart attacks and strokes prevented in the two programmes.
Results Assuming 100% uptake and adherence to the screening protocol, in every 1000 persons, the NHS Health Check Programme would prevent 287 cases of a heart attack or stroke in individuals who would gain on average about 4 years of life without a heart attack or stroke, the precise gain depending on the extent of treatment for those with raised blood pressure, and 136 would be prescribed statins with no benefit. The corresponding figures for the Polypill Prevention Programme are 316 individuals who would, on average, gain 8 years of life without a heart attack or stroke with 260 prescribed the polypill with no benefit. Based on published estimates of uptake and adherence to of the NHS Health Check programme, only 24 cases per 1000 are currently benefitting instead of 287. This result could be achieved in the Polypill Prevention Programme with just 8% (24/316) of the eligible population taking part.
Conclusions The Polypill Prevention Programme is by design simpler with the potential of preventing many more heart attacks and strokes; even an uptake of 40% would represent a 5-fold greater preventive effect than the NHS Health Check Programme.
Competing Interest Statement
NW is a Director of Polypill Ltd which runs the UK Polypill Prevention Programme. ADH is a member of the Advisory Group for the Industrial Strategy Challenge Fund Accelerating Detection of Disease Challenge, and a co-opted member of the National Institute for Health and Care Excellence Guideline update group for Cardiovascular disease: risk assessment and reduction, including lipid modification, CG181.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
